Scientific Sessions 2025  /  Shifting Paradigms in Lipid Management for ASCVD Risk  /  Lp(a) and ASCVD: What does the causal link mean for risk reduction in practice?
Logo

American Heart Association

  65
  0

Final ID:

Lp(a) and ASCVD: What does the causal link mean for risk reduction in practice?

  • O'donoghue, Michelle  ( BRIGHAM WOMENS HOSP , BOSTON , Massachusetts , United States )
    • Author Disclosures:
    Michelle O'Donoghue: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Amgen:Past (completed) ; Consultant:New Amsterdam:Active (exists now) ; Consultant:Verve:Active (exists now) ; Consultant:NovoNordisk:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Research Funding (PI or named investigator):Marea:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Shifting Paradigms in Lipid Management for ASCVD Risk

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Main Event

More abstracts on this topic:
Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults with or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial

Navar Ann Marie, Mendizabal Geraldine, Nuez Llota Julio, Zhu Pengfei, Zhuo Min, Ballantyne Christie, Mikhailova Elina, Catapano Alberico, Banka Puja, Blom Dirk, Cadena Alberto, Kourpanidis Susan, Lepor Norman, Tsukamoto Kazuhisa

From management to cure? Assessing the promise of gene therapy for hyperlipidemia

Musunuru Kiran

More abstracts from these authors:
The New Guideline in a Global Context: Writing Committee Reply

O'donoghue Michelle, Sandner Sigrid, Tamis-holland Jacqueline

Discussant: LIBerate-OLE, LIBerate-HeFH_OLE

O'donoghue Michelle

You have to be authorized to contact abstract author. Please, Login
Not Available